Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,427 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication Therapy Management Clear all
Recruiting Not applicable Interventional

Embolization for the Treatment of Heel Pain Secondary to Plantar Fasciitis

NCT06805942
View directory record Official record
Conditions
Plantar Fasciitis of Both Feet
Interventions
Lipiodol (ethiodized oil) injection
Device
Lead sponsor
IR Centers
Other
Eligibility
22 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Phase 1 Interventional

SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

NCT01749969
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
isatuximab SAR650984, lenalidomide, dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
San Francisco, California • Tampa, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 22, 2026, 11:53 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

NCT01875003
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo, Standard of Care
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 17 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Mission Viejo, California • Stockton, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 22, 2026, 11:53 AM EDT
Terminated Phase 3 Interventional Results available

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

NCT04197986
View directory record Official record
Conditions
Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
Interventions
Infigratinib, Placebo
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
47
States / cities
Tucson, Arizona • Duarte, California • Loma Linda, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 22, 2026, 11:53 AM EDT
Completed No phase listed Observational

Comparison of Epidural and TAP Block in Abdominal Surgery

NCT01848951
View directory record Official record
Conditions
Acute Pain, Surgery, Regional Anesthesia
Interventions
Epidural, TAP Block
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 22, 2026, 11:53 AM EDT
Recruiting Early Phase 1 Interventional

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

NCT02446431
View directory record Official record
Conditions
Solid Tumor
Interventions
Bevacizumab, Cyclophosphamide, Valproic Acid, Temsirolimus
Drug
Lead sponsor
Miller Children's & Women's Hospital Long Beach
Other
Eligibility
12 Months to 31 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
2
States / cities
Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Phase 4 Interventional Results available

Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome

NCT00266656
View directory record Official record
Conditions
Turner Syndrome
Interventions
Humatrope
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
4 Years to 20 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Not applicable Interventional Results available

Co-Use of Opioid Medications and Alcohol Prevention Study

NCT05599672
View directory record Official record
Conditions
Alcohol Drinking, Opioid Use
Interventions
Alcohol-targeted Brief Intervention-Medication Therapy Management, Standard medication counseling
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 22, 2026, 11:53 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

NCT04965454
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
Fluorine-18 fluorocholine
Combination Product
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Phase 2 Interventional

Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer

NCT00006105
View directory record Official record
Conditions
Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions
amifostine trihydrate, cisplatin, gemcitabine hydrochloride, adjuvant therapy
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers

NCT03827629
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Treatment A: Naloxone Nasal Spray, Treatment B: Naloxone Nasal Spray, Treatment C: Naloxone HCL Intramuscular (IM) Injection
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen

NCT02848729
View directory record Official record
Conditions
Pain
Interventions
Oral Acetaminophen, IV Acetaminophen, IV Morphine, Placebo Tablets, Saline
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Tucson, Arizona • Naples, Florida • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)

NCT03786770
View directory record Official record
Conditions
Frown Lines
Interventions
DaxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boca Raton, Florida • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Not applicable Interventional

Treatment of Opioid Use: Medication Adherence Therapy

NCT03567356
View directory record Official record
Conditions
Opioid Dependence, Opioid-Related Disorders
Interventions
MAT-PLUS "Helping Hands"
Other
Lead sponsor
Potomac Health Foundations
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Phase 1Phase 2 Interventional

Liver Transplantation With Tregs at MGH

NCT03577431
View directory record Official record
Conditions
Liver Transplant
Interventions
arTreg-CSB, leukapheresis, cyclophosphamide, mesna, everolimus
Biological · Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

NCT02782741
View directory record Official record
Conditions
Glycogen Storage Disease Type II;Pompe's Disease
Interventions
Avalglucosidase alfa (GZ402666), Alglucosidase alfa (GZ419829)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
3 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Electrophysiological Effects of Potential QT Prolonging Drugs

NCT05716854
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Clarithromycin, Pimozide, Placebo (Part 1), Moxifloxacin, Cobicistat, Moxifloxacin and Cobicistat, Placebo (Part 2)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Habit Formation for Diabetes Self-Management

NCT05455242
View directory record Official record
Conditions
Diabete Type 2
Interventions
Habit formation
Behavioral
Lead sponsor
Des Moines University
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

NCT00803686
View directory record Official record
Conditions
Phase 1 Pharmacodynamic Study
Interventions
Oral rsCT tablet, Oral Placebo Tablet, Fortical (rsCT) nasal spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 22, 2026, 11:53 AM EDT
Recruiting Phase 4 Interventional

Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)

NCT07145866
View directory record Official record
Conditions
Nicotine Dependence, Transcranial Magnetic Stimulation, Vaping, Smoking Cessation, Smoking (Tobacco) Addiction
Interventions
Varenicline, Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham, Nicotine Cessation Counseling, D-cycloserine
Drug · Device · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 11:53 AM EDT
Completed Phase 3 Interventional Results available

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

NCT02621931
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
179
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 22, 2026, 11:53 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Positron Emission Tomography (PET) Imaging Studies With NIS Reporter

NCT02907073
View directory record Official record
Conditions
Myeloma, Endometrial Cancer
Interventions
BF4
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 22, 2026, 11:53 AM EDT
Recruiting Not applicable Interventional

A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients

NCT06424522
View directory record Official record
Conditions
Low Anterior Resection Syndrome, Rectal Carcinoma
Interventions
Dietary Fiber, Enema Administration, Loperamide Hydrochloride, Physical Therapy, Questionnaire Administration, X-Ray Imaging
Dietary Supplement · Procedure · Drug + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 11:53 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant

NCT03386305
View directory record Official record
Conditions
Post Liver Transplant
Interventions
EnvarsusXR, Tacrolimus
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 22, 2026, 11:53 AM EDT